Hoffmann-la Roche Inc.

Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Christophe Michoud

Kin-Chun Thomas Luk

Kenneth Carey Rupert

Yan Lou

Stacy W Remiszewski

Kang Le

Shaoqing Chen

Xiaochun Han

Li Chen

Yi Heng Chen

David Michael Goldstein

Paul Gillespie

Achyutharao Sidduri

Steven Gregory Mischke

Robert Francis Kester

Jin-Jun Liu

Wylie Solang Palmer

Andrew Forrest Donnell

James Patrick Dunn

Robert Alan Goodnow, Jr

Nader Fotouhi

David Robert Bolin

Norman Kong

Weiya Yun

Leyi Gong

John Frederick Boylan

Kshitij Chhabilbhai Thakkar

Joan Heather Hogg

Emily Aijun Liu

Tania M Silva

Jianping Cai

John Anthony Moliterni

Andrzej Robert Daniewski

Teresa Alejandra Trejo-Martin

Pamela Loreen Rossman

Apostolos Dermatakis

Marek Michal Kabat

Lubica Raptova

William Harris

Martin Weisel

Parcharee Tivitmahaisoon

Levi Gong

Kenneth C Rupert

Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R, R, R, Rand Rare as described in this application, and methods of using said compounds in the treatment of cancer. 

Tetrahydro-benzodiazepinones

Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R, R, Rand Rare described in this application, and methods of using said compounds in the treatment of cancer. 

Antiproliferative benzo [B] azepin-2-ones

There are provided compounds of the formula 

Substituted hetero-azepinones

Compounds of formula I modulate jnk and cdk: or a pharmaceutically acceptable salt thereof, where R, R, R, R, and m are defined herein.

Benzotriazole kinase modulators

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

Thiazole and thiophene compounds

Compounds of formula I modulate JNK: wherein the variables are as defined herein.

JNK modulators

The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.

Thiazolyl-benzimidazoles

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Diacylglycerol acyltransferase inhibitors

Thiazolinone disubstituted quinoline derivatives where the quinoline ring is disubstituted at the 3, 4 positions which derivatives demonstrate CDK1 antiproliferative activity and are useful as anti-cancer agents.

Thiazolinone 3,4-disubstituted quinolines

Thiazolinone substituted quinoline derivatives where the quinoline ring is substituted at the 2 position which derivatives demonstrates CDK1 antiproliferative activity and are useful as anti-cancer agents.

Thiazolinone 2-substituted quinolines

Disclosed are novel pyrimido compounds that are selective inhibitors of both KDR and FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer.

Pyrimido compounds having antiproliferative activity

Disclosed are novel pyrimido compounds that are selective inhibitors of both KDR an FGFR kinases and are selective against LCK. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer.

Disclosed are novel 4,5-pyrazinoxindoles having the formula

4,5-pyrazinoxindoles

Disclosed are novel 4,5-azolo-oxindoles having the formula ##STR1## These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. Thus, these compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical compositions containing these compounds, and methods for the treatment and/or prevention of cancer, particularly in the treatment or control of solid tumors using these compounds, as well as intermediates useful in the preparation of compounds of formula I.

4,5-azolo-oxindoles

Growing community of inventors

New York, NY, United States of America

Christophe Michoud